EODData

NASDAQ, REVB:

04 Sep 2025
LAST:

2.800

CHANGE:
 0.07
OPEN:
2.740
HIGH:
2.830
ASK:
0.000
VOLUME:
83.4K
CHG(%):
2.56
PREV:
2.730
LOW:
2.650
BID:
0.000
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Sep 252.7402.8302.6502.80083.4K
03 Sep 252.7302.8002.6602.73045.5K
02 Sep 252.7002.7502.6102.70047.6K
29 Aug 252.8502.8502.7002.76068K
28 Aug 252.7602.8802.6912.79020.9K
27 Aug 252.6902.8002.5602.73089.2K
26 Aug 252.8792.8792.5002.788128.5K
25 Aug 252.8802.8802.7602.84563.8K
22 Aug 252.7002.9302.6242.930194.1K
21 Aug 252.5202.6302.5002.54046.9K

COMPANY PROFILE

Name:
About:Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:4660 La Jolla Village Drive, San Diego, CA, United States, 92122
Website:https://www.revbiosciences.com
CUSIP:76135L101
CIK:0001810560
ISIN:US76135L1017
FIGI:BBG00WH4GBZ2

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

P/E Ratio:0.00
Price to Book:1.12
Price to Sales:2.88
Shares:1.7M
Market Cap:4.76M

TECHNICAL INDICATORS

MA5:2.76
MA10:2.76
MA20:2.64
MA50:2.43
MA100:2.27
MA200:2.19
STO9:43.48
STO14:67.50
RSI14:59.48
WPR14:-32.50
MTM14:0.22
ROC14:0.09
ATR:0.21
Week High:2.88
Week Low:2.61
Month High:2.93
Month Low:2.26
Year High:4.70
Year Low:0.23

RECENT SPLITS

Date Ratio
07 Jul 20251-3
28 Jan 20251-16
25 Jan 20241-30
01 Feb 20231-35